ABC | Volume 113, Nº4, October 2019

Original Article Şahiner et al LAA occlusion with amulet device Arq Bras Cardiol. 2019; 113(4):712-721 1. Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 2000;27(3):257-67. 2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1-88. 3. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al, Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157-64. 4. Connolly SJ, EzekowitzMD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. 5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011. 365(11):981-92. 6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10): 883-91. 7. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/AmericanHeart Association Task Force on PracticeGuidelines and theHeart RhythmSociety. J Am Coll Cardiol. 2014;64(21):e1-76. 8. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostaticmedicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):p.692-4. 9. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988-98. 10. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of theWatchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. 11. Guérios ÊE, Chamié F, MontenegroM, Saad EB, Brito Jr FS , Caramori PA, et al. First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. Arq Bras Cardiol. 2017;109(5):440-7. 12. Landmesser U, Schmidt B, Nielsen-Kudsk JE, Lam SC, Park JW, Tarantini G, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017;13(7):867-76. 13. Freixa X, Abualsaud A, Chan J, Nosair M, Tzikas A, Garceau P, et al. Left atrial appendage occlusion: initial experience with the Amplatzer Amulet. Int J Cardiol. 2014;174(3):492-6. 14. RegueiroA,Cruz-GonzalezI,BethencourtA,Nombela-FrancoL,Champagne J, Asmarats L, et al. Long-term outcomes following percutaneous left atrial appendage closure in patients with atrial fibrillation and contraindications to anticoagulation. J Interv Card Electrophysiol. 2018;52(1):53-9. 15. Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN. Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes. Circulation. 2018;138(9):874-85. 16. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, et al. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. J Am Coll Cardiol. 2018;71(14):1528-36. 17. CostaMJ,FerreiraE,QuintellaEF,AmorimB,FuchsA,ZajdenvergR,etal.LeftAtrial AppendageClosurewithAmplatzerCardiacPluginNonvalvularAtrialFibrillation: SafetyandLong-TermOutcome.ArqBrasCardiol.2017;109(6):541-9. 18. Bianchi G, Solinas M, Gasbarri T, Bevilacqua S, Tiwari KK, Berti S, et al. Pulmonary artery perforation by plug anchoring system after percutaneous closure of left appendage. Ann Thorac Surg. 2013;96(1):e3-5. 19. Suwalski G, Wojnowski A, Mizerski J, Gryszko L. Delayed Pulmonary Artery Perforation With Left Atrial Appendage Occluder Hooks. Ann Thorac Surg. 2016; 101(2):e37-9. 20. Halkin A, Cohen C, Rosso R, Chorin E, Schnapper M, Biner S, et al. Left atrial appendage and pulmonary artery anatomic relationship by cardiac- gated computed tomography: Implications for late pulmonary artery perforation by left atrial appendage closure devices. Heart Rhythm. 2016;13(10):2064-9. 21. Klug D, Commeau P, Defaye P, Thambo JB, Gras D, Aubry P, et al. Percutaneous occlusion of the left atrial appendage: An expert consensus statement. Arch Cardiovasc Dis. 2015;108(8-9):460-7. 22. Aytemir K, Aminian A, Asil S, Canpolat U, Kaya EB, Şahiner L, et al. First case of percutaneous left atrial appendage closure by amulet device in a patient with left atrial appendage thrombus. Int J Cardiol. 2016 Nov;223:28-30. 23. Tarantini G, D’Amico G, Latib A, Montorfano M, Mazzone P, Fassini G, et al. Percutaneous left atrial appendage occlusion in patients with atrial fibrillation and left appendage thrombus: feasibility, safety and clinical efficacy. EuroIntervention. 2018;13(13):1595-602. References 720